Canadian Cancer Trials Group / Groupe canadien des essais sur le cancer

NEUROENDOCRINE DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON
ROOM: CHURCHHILL "B"

SATURDAY APRIL 26TH, 2025 2:00 PM – 3:00 PM

CO-CHAIRS : DR SIMRON SINGH & DR TIM ASMIS
SENIOR INVESTIGATOR: DR CHRIS O'CALLAGHAN

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by Queen's University.

Learning Objectives:
- *To identify and address, through clinical and translational research, the disease burden associated with neuroendocrine malignancies in Canada.*
- *To identify clinical trial research opportunities in neuroendocrine malignancies within the Canadian Cancer Trials Group.*
- *To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct as these relate to neuroendocrine malignancies.*
- *To integrate and apply new clinical trial methodologies in neuroendocrine malignancies in the Canadian Cancer Trials Group research agenda.*
- *To identify mentoring opportunities for new investigators.*

Time	Topic	Speaker
2:00 pm	**Welcome**	
2:00 pm	**NE.1 (NETRETREAT): A Phase II RCT of Lu-177 DOTATATE Retreatment vs. Everolimus in metastatic/unresectable small bowel NET**	**Dr S Singh**
2:15 pm	**NE.2 (STOPNET-AGITG): A Randomized Study of Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine Tumours**	**Dr R Goodwin** **Dr J Loree**
2:30 pm	**COMMNETs – Commonwealth Neuroendocrine Tumour Collaboration Update**	**Dr T Asmis**
2:40 pm	**AGITG CORONET: Randomized Phase II/III study of peptide receptor radionuclide therapy (PRRT) and CAPTEM chemotherapy v PRRT alone in patients with pancreatic neuroendocrine neoplasms (pNENs) progressing on first line SSA therapy**	**Dr C Karapetis**
3:50 pm	**NCTN Neuroendocrine Task Force Update**	**Dr S Singh**
3:00 pm	**Meeting Adjourned**	